Biotech And The Inflation Reduction Act: Sussing Out The IRA

Source: TD Cowen Insights Podcast 

John Murphy, Chief Policy Officer & Healthcare Counsel at the Biotechnology Innovation Organization (BIO) speaks with Yaron Werber, Biotechnology Analyst about how the Inflation Reduction Act (IRA) will impact innovation in biotech

They discuss drug pricing reform provisions of the IRA, including drug exclusion, calculation of maximum fair price, and small molecule vs biologics. They also look at how those provisions might impact incentive structures in drug development, the likelihood of revisions to the bill near term, its potential effects on formulary or benefit design, and the first wave of IRA litigation.

CLICK HERE to listen to the podcast.